Related Experiment Video
Updated: Nov 8, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C in Tunisia from 1991 to 2019: A systematic review
Insights
Hepatitis C virus (HCV) infection is a significant cause of liver disease in Tunisia. This review highlights a low prevalence in the general population but higher rates in at-risk groups, with limited research on new treatments.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Hepatitis C virus (HCV) is a major contributor to chronic liver disease and liver cancer mortality in Tunisia.
- Tunisia demonstrates a low endemicity for HCV in the general population, with prevalence not exceeding 1%.
Purpose of the Study:
- To conduct a systematic review of viral hepatitis C research in Tunisia from 1991 to 2019.
- To consolidate current knowledge on HCV epidemiology, genotypes, and treatment efficacy in Tunisia.
Main Methods:
- A comprehensive search of HCV-specific literature published between 1991 and 2019 was performed.
- Bibliographic databases were utilized to identify relevant studies on hepatitis C in Tunisia.
Main Results:
- HCV prevalence is below 1% in the general Tunisian population but higher in high-risk groups like hemodialysis and polytransfused patients.
- Genotype 1, particularly subtype 1b, is predominant, with limited circulation of other genotypes.
- Studies primarily focused on conventional therapy (pegylated IFN + ribavirin), predictive factors for sustained virologic response (SVR), and resistance mutations.
Conclusions:
- The literature review provides an updated overview of the hepatitis C situation in Tunisia.
- There is a notable absence of research on the effectiveness of novel direct-acting antivirals (DAAs) in the Tunisian context.
Background:
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease and liver cancer related deaths in Tunisia.
Aim:
Perform a systematic review on viral hepatitis C in Tunisia between 1991 and 2019.
Methods:
A global search of HCV-specific documentation in Tunisia (1991-2019) in bibliographic data search sites.
Results:
Tunisia is a low endemic country for hepatitis C with a prevalence that not exceed 1% in the general population. Several studies have focused on populations at risk of HCV contamination such as hemodialysis and polytransfused patients. The prevalence of hepatitis C is higher in these groups. In relatively small series, a clear predominance of genotype 1 and subtype 1b has been reported in Tunisia with a lower co-circulation of the other genotypes. Several polymorphisms of cytokine and chemokine genes can influence the clearance or persistence of HCV infection. Tunisian studies have focused on the efficacy of conventional dual therapy (pegylated IFN + ribavirin) by analyzing the predictive factors linked to SVR and mutations associated with resistance to viral inhibitors. No publication has discussed the effectiveness of new direct-acting antivirals in Tunisia.
Conclusion:
This review of the literature provides an update on the status of hepatitis C in Tunisia and reveals a lack of investigations on new direct-acting antivirals.
Related Concept Videos
01:10Retrovirus Life Cycles
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test